D.A. Davidson & Co. Denali Therapeutics Inc. Transaction History

D.A. Davidson & Co.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 29, 2019	SELL	$13.88 - $21.75 $219,762 - $344,367	-15,833 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$12.46 - $21.74 $62,511 - $109,069	-5,017 Reduced 24.06%	15,833 $344,000
Q2 2018 Aug 02, 2018	BUY	$15.25 - $21.02 $165,462 - $228,067	10,850 Added 108.5%	20,850 $318,000
Q1 2018 May 04, 2018	BUY	$15.36 - $24.8 $153,600 - $248,000	10,000 New	10,000 $197,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.